What is iQure Pharma?
iQure Pharma is a clinical-stage biotechnology firm dedicated to pioneering treatments for central nervous system (CNS) conditions. The company's core strategy revolves around restoring glutamate homeostasis, a critical mechanism in preventing neuronal damage. Its lead candidate, iQ-007, is a first-in-class small molecule currently undergoing Phase 1 clinical trials for treatment-resistant epilepsy. This therapeutic agent is designed to enhance the function of the primary glutamate transporter, thereby mitigating excitotoxicity, a process implicated in neurodegenerative diseases and chronic pain. iQure Pharma actively engages with leading research institutions to validate its scientific foundation and broaden its pipeline of potential treatments.
How much funding has iQure Pharma raised?
iQure Pharma has raised a total of $1.8M across 2 funding rounds:
Series A
$600K
Other Financing Round
$1.2M
Series A (2022): $600K with participation from Keiretsu Forum Mid-Atlantic
Other Financing Round (2023): $1.2M, investors not publicly disclosed
Key Investors in iQure Pharma
Keiretsu Forum Mid-Atlantic
Keiretsu Forum Mid-Atlantic is an angel investor network that provides capital and strategic guidance to early-stage companies. Their involvement suggests a focus on supporting innovative ventures with strong scientific backing.
What's next for iQure Pharma?
With the recent influx of major strategic investment, iQure Pharma is poised to accelerate the development of its promising CNS therapies. The substantial enterprise-level funding will likely be allocated towards advancing iQ-007 through its clinical trial phases, potentially expanding its indications to other neurodegenerative conditions. Further investment will also support the expansion of the company's research and development pipeline, exploring new therapeutic targets within the complex landscape of neurological disorders. This strategic financing positions iQure Pharma to make significant strides in addressing unmet medical needs in the CNS space.
See full iQure Pharma company page
